Evidence map›Paper›PMID 42159413›Full record

ArticleJournal of virology2026

Tonic and early interferons defend against respiratory viruses in primary human lung organoid-derived air-liquid interface cultures.

Rinu Sivarajan, Paul C Kirchgatterer, Jan Lawrenz, Eszter Tanner-Matiz, Jessica Lindenmayer, Verena Renz, Tapan Joshi, Heike Oberwinkler, Thorsten Walles, Giorgio Fois and 6 more

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rinu SivarajanInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.ORCID 0009-0000-3656-9985
Paul C KirchgattererResearch Institute of Molecular Pathology, Vienna BioCenter, Vienna, Austria.
Jan LawrenzInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Eszter Tanner-MatizInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Jessica LindenmayerULMTeC Core Facility Organoids, Ulm University Medical Faculty, Ulm, Germany.
Verena RenzULMTeC Core Facility Organoids, Ulm University Medical Faculty, Ulm, Germany.
Tapan JoshiULMTeC Core Facility Organoids, Ulm University Medical Faculty, Ulm, Germany.
Heike OberwinklerDepartment of Oto-Rhino-Laryngology, Head and Neck Surgery, University Hospital Würzburg, Würzburg, Germany.
Thorsten WallesDepartment of Thoracic Surgery, University Medicine Magdeburg, Magdeburg, Germany.
Giorgio FoisInstitute for General Physiology, University of Ulm, Ulm, Germany.
Alexander KlegerULMTeC Core Facility Organoids, Ulm University Medical Faculty, Ulm, Germany.
Manfred FrickInstitute for General Physiology, University of Ulm, Ulm, Germany.
Jan MünchInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.ORCID 0000-0001-7316-7141
Moritz M GaidtResearch Institute of Molecular Pathology, Vienna BioCenter, Vienna, Austria.
Maria SteinkeDepartment of Oto-Rhino-Laryngology, Head and Neck Surgery, University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0003-2675-1374
Konstantin M J SparrerInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.ORCID 0000-0002-8682-1779

Funding

Baden-Württemberg Stiftung (BWS) AutophagyBoostBMFTR IMMUNOMOD-01KI2014Deutsche Forschungsgemeinschaft (DFG) CRC1279 SP 1600/7-1 SP 1600/9-1 SP 1600/13-1ERC Guardians 101117146
6 · The paper itself

Abstract

Innate defenses of the respiratory epithelium are the first barrier against incoming respiratory viruses. To understand the contribution of both basal (tonic) and induced interferon (IFN) to antiviral defenses in a physiologically relevant system, we established air-liquid interface (ALI) cultures of primary human bronchial epithelium (HBE) and small airway epithelium (HSE). Via an organoid intermediate stage, the limited healthy donor material was expanded while preserving stemness, and subsequently differentiated. Characterization by immunofluorescent profiling and transcriptomic analyses showed that the cellular diversity and architecture of our ALI cultures were comparable to native human lung epithelium. Infection with human rhinovirus (HRV16) induced a strong and early IFN response, whereas human coronavirus (HCoV-229E and HCoV-NL63) infection caused a more subdued and delayed response. HRV16, but not HCoV-229E, infection was eventually cleared from the cultures after more than 30 days. Depletion of tonic or early type I/III IFNs using neutralizing antibodies or scavengers increased infectious HRV production by ~10- or ~1,000-fold, respectively, suggesting a role of IFNs in clearance. Taken together, we present a method for generating primary lung epithelial air-liquid interface cultures that retain effective IFN responses, demonstrate clearance of HRV by innate defenses, and highlight the importance of tonic and early IFN.IMPORTANCEMild respiratory viral infections, for example, with human common cold coronaviruses or rhinoviruses, are a massive cause of human morbidity. The respiratory tract is the primary entry route for these viruses and also the contact site for initial innate immune defenses. Here, we show that primary human lung epithelial cell-derived air-liquid interface cultures mimic the architecture and cell composition of native human lung epithelium, and retain both induced and tonic interferon (IFN) responses. Notably, our data show that the model's innate immune defense, characterized by rapid and robust IFN responses, are sufficient to clear human rhinovirus (HRV) infections but not human coronavirus 229E. Finally, depletion of induced or tonic IFNs led to a marked increase in HRV infection. Thus, our data suggest that tonic low levels of IFNs contribute to the epithelial defense against viruses, maintaining the tissue's immune readiness.

Indexed as

InterferonsLungOrganoidsRespiratory MucosaRhinovirusCells, CulturedCoronavirus 229E, HumanCoronavirus NL63, HumanEpithelial CellsHumansImmunity, InnateInterferonsair-liquid interface modelscoronaviruslung epitheliumrhinovirustonic interferonvirus

Identifiers

PMID42159413
PMCPMC13288630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.